GA
PCRX icon

Gagnon Advisors’s Pacira BioSciences PCRX Stock Holding History

Gagnon Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.95M Hold
352,637
– – 5.69% 7
2026
Q1 		$7.97M Buy
352,637
+91,729
+35% +$2.04M 5.86% 8
2025
Q4 		$6.75M Buy
260,908
+47,506
+22% +$1.13M 4.29% 11
2025
Q3 		$5.5M Hold
213,402
– – 3.4% 14
2025
Q2 		$5.1M Buy
213,402
+80,012
+60% +$2.02M 3.43% 14
2025
Q1 		$3.31M Hold
133,390
– – 2.34% 19
2024
Q4 		$2.51M Hold
133,390
– – 1.61% 23
2024
Q3 		$2.01M Hold
133,390
– – 1.3% 24
2024
Q2 		$3.82M Hold
133,390
– – 2.91% 19
2024
Q1 		$3.9M Hold
133,390
– – 3.38% 15
2023
Q4 		$4.5M Sell
133,390
-46,941
-26% -$1.37M 3.93% 14
2023
Q3 		$5.53M Hold
180,331
– – 4.63% 10
2023
Q2 		$7.23M Hold
180,331
– – 4.84% 9
2023
Q1 		$7.36M Hold
180,331
– – 4.94% 7
2022
Q4 		$6.96M Hold
180,331
– – 4.7% 10
2022
Q3 		$9.59M Sell
180,331
-55,114
-23% -$3.06M 6.21% 3
2022
Q2 		$13.7M Sell
235,445
-15,695
-6% -$1.03M 8.31% 1
2022
Q1 		$19.2M Hold
251,140
– – 8.83% 1
2021
Q4 		$15.1M Buy
251,140
+10,998
+5% +$606K 6% 2
2021
Q3 		$13.4M Buy
240,142
+26,925
+13% +$1.55M 5.33% 5
2021
Q2 		$12.9M Buy
213,217
+19,357
+10% +$1.23M 4.92% 6
2021
Q1 		$13.6M Hold
193,860
– – 5.59% 4
2020
Q4 		$11.6M Hold
193,860
– – 5.21% 6
2020
Q3 		$11.7M Hold
193,860
– – 7.15% 3
2020
Q2 		$10.2M Hold
193,860
– – 7.32% 4
2020
Q1 		$6.5M Hold
193,860
– – 6.07% 4
2019
Q4 		$8.78M Hold
193,860
– – 4.92% 8
2019
Q3 		$7.38M Buy
193,860
+86,448
+80% +$3.45M 4.58% 7
2019
Q2 		$4.67M Buy
+107,412
New +$4.56M 2.67% 21

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gagnon Advisors's PCRX Position: Q2 2026 in Review

Gagnon Advisors held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 352,637 shares worth $8.95M. The position accounts for 5.69% of the portfolio, ranked #7.

Gagnon Advisors first reported a position in PCRX in Q2 2019 and has held it in 29 quarters since. The position peaked at $19.2M in Q1 2022. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Gagnon Advisors held 352,637 shares of Pacira BioSciences worth $8.95M as of Q2 2026.
  • Gagnon Advisors left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up 5.69% of Gagnon Advisors's portfolio in Q2 2026, its #7 holding.
  • Gagnon Advisors first reported a position in Pacira BioSciences in Q2 2019 and has held it in 29 quarters since.
  • Gagnon Advisors's Pacira BioSciences position peaked at $19.2M in Q1 2022.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Gagnon Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.